The invention provides application of an
adenosine receptor inhibitor in preparation of a
medicine for treating
hyperlipidemia and cardiovascular and cerebrovascular diseases. The GPR146 is a GPCR
orphan receptor which is found in the earlier stage and used for regulating blood
lipid metabolism. In a process of screening an endogenous ligand of GPR146, we accidentally find that GPR146 can form a functional complex with another GPCR family member A2AR to jointly respond to activation of
adenosine. The
adenosine inhibitor can achieve a remarkable blood fat reducing effect, a key theoretical basis is laid for developing the blood fat reducing
medicine targeting GPCR, and the adenosine inhibitor can be widely applied to treatment of
hyperlipidemia and related cardiovascular and cerebrovascular diseases.